CNS Pharmaceuticals's total assets for Q4 2024 were $8.70M, an increase of 17.43% from the previous quarter. CNSP total liabilities were $2.52M for the fiscal quarter, a -37.78% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.